Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy

A Randomized, Double-Blind, Triple-Dummy, 3-Period Crossover Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Formulation of MOA-728 in Subjects on Stable Methadone Maintenance

To evaluate the effects of single oral doses of MOA-728 compared to a positive control in subjects on methadone therapy.

Inclusion:

1. Healthy men or women, aged 18 to 65 years.
2. History of methadone treatment for at least 1 month, at a dose >=30 and <=140 mg/day.

Exclusion:

1. History or active presence of clinically important medical disease.
2. Allergy to opioids.